Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) EBIT (2018 - 2025)

Historic EBIT for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to -$6.4 million.

  • Serina Therapeutics' EBIT fell 2033.13% to -$6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.4 million, marking a year-over-year decrease of 10753.24%. This contributed to the annual value of -$17.0 million for FY2024, which is 44483.86% down from last year.
  • Per Serina Therapeutics' latest filing, its EBIT stood at -$6.4 million for Q3 2025, which was down 2033.13% from -$5.6 million recorded in Q2 2025.
  • Over the past 5 years, Serina Therapeutics' EBIT peaked at $241000.0 during Q4 2023, and registered a low of -$6.4 million during Q3 2025.
  • For the 5-year period, Serina Therapeutics' EBIT averaged around -$2.8 million, with its median value being -$2.1 million (2022).
  • In the last 5 years, Serina Therapeutics' EBIT surged by 11352.41% in 2023 and then plummeted by 240248.96% in 2024.
  • Serina Therapeutics' EBIT (Quarter) stood at -$1.9 million in 2021, then rose by 4.55% to -$1.8 million in 2022, then surged by 113.52% to $241000.0 in 2023, then plummeted by 2402.49% to -$5.5 million in 2024, then decreased by 15.19% to -$6.4 million in 2025.
  • Its EBIT stands at -$6.4 million for Q3 2025, versus -$5.6 million for Q2 2025 and -$5.9 million for Q1 2025.